Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.68 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.68 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220223 | 0.89 | QPCT (0.65) | QPCTQPCTLCYP17A1SMN1; SMN2KDM4E | |
| SCHEMBL3218135 | 0.81 | QPCT (0.72) | QPCTQPCTLSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3217600 | 0.80 | QPCT (0.62) | QPCTQPCTLCYP17A1KDM4EALDH1A1 | |
| SCHEMBL3227909 | 0.78 | QPCT (0.64) | QPCTQPCTLCYP17A1SRC | |
| SCHEMBL3260750 | 0.74 | QPCT (0.67) | QPCTQPCTLCYP17A1SRC | |
| SCHEMBL3231053 | 0.73 | QPCT (0.66) | QPCTQPCTLCYP17A1KDM4EALDH1A1 | |
| SCHEMBL3215934 | 0.73 | QPCT (0.66) | QPCTQPCTLCYP17A1SMN1; SMN2KDM4E | |
| SCHEMBL3229481 | 0.72 | QPCT (0.54) | QPCTQPCTLCYP17A1MAPK1 | |
| SCHEMBL3224645 | 0.72 | QPCT (0.72) | QPCTQPCTLSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3228868 | 0.71 | QPCT (0.52) | QPCTQPCTLSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | claimed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | claimed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | claimed |
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-2118101-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | QPCT 4475/4885QPCTL 4381/4885CYP17A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.